Avalon Globocare Corp. · NASDAQ:ALBT
Avalon Globocare — Investor Presentation (March 2019)
43 slides from Avalon Globocare's investor presentation, Mar 8, 2019
Slide 1: Avalon GloboCare Corp. Corporate Presentation March 2019
. . AVALON GLOBOCARE CORP. Corporate Presentation March 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation may constitute “forward-looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual
Slide 3: Corporate Overview
Corporate Overview . Founded in 2016, Avalon GloboCare Corp. (Nasdaq: AVCO) is a leading cell-based technology company headquartered in New Jersey, USA . Innovative and transformative cellular technology platforms focusing on exosome diagnostics (“liquid biopsy”), regenerative therapeutics, & cellul
Slide 4: Avalon Timeline & Milestones
Avalon Timeline & Milestones (@ Patent filings: AVA 101 (CAR-T), miR-185 for Oral Cancer (Exosome) Established joint venture with Arbele Corp.; co- a3 development of next-generation CAR-T therapy @ UPlisted to NASDAQ Capital Market (Nasdaq: AVCO) Established cGMP, FACT-compliant bio-manufacturing &
Slide 5: Senior Management Team
Senior Management Team Daniel Lu Professor Daopei Lu, M.D. Co-founder, Chairman of the Board Scientific Founder Chairman of Lu Daopei Medical Group David Jin, M.D., Ph.D. Team of Our Subsidiaries Co-founder, CEO, President, BoD Co-CEO, Genexosome Technologies Yu Zhou, M.D., Ph.D. U.S. Licensed Physi
Slide 6: Board of Directors
Board of Directors AVALON 48 th) i. Daniel Lu Chairman of the Board Congressman Billy Tauzin Director; Former U.S. Congressman; Former President of PhRMA David Jin, M.D., Ph.D. Director, CEO, President Tevi Troy, Ph.D. Director; Chairman of Nomination/Governance Committees Former Deputy Director of
Slide 7: Our Scientific Founder: Professor Daopei Lu, M.D.
Our Scientific Founder: Professor Daopei Lu, M.D. Co-founded National Bone Marrow & Cord Blood Registry in China Founded the China Bone Marrow Donor Program “Father of Hematopoietic Stem Cell Transplant” in China Member of Chinese Academy of Engineering CIBMTR “Distinguished Life Contribution Award”
Slide 8: Our Clinical Bases in China
Our Clinical Bases in China ) °? Lu Daopei Hospital Network Jie @ a, Pi ak Beijing Lu Daopei Hospital Hebei Yanda Lu Daopei Hospital Hubei Provincial Stem Cell Bank, Wuhan Biolake Lu Daopei Medical Group Lu Daopei Hematology Research Institute, Beijing Over 100 affiliated hospital network (Hematopat
Slide 9: Our Scientific & Clinical Advisory Board
Our Scientific & Clinical Advisory Board James Gajewski, M.D. Shahin Rafii, M.D.* Yen-Michael Hsu, M.D., Ph.D.* Wenchun Qu, M.D., Ph.D. Peihua Peggy Lu, M.D. Xin Lin, Ph.D. --- Head of Advisory Board; Former MD Anderson Medical Director --- Weill Cornell; Director of Ansary Stem Cell Institute, HHMI
Slide 10: Headquarters / Administrative Office
Headquarters / Administrative Office Worldwide Headquarters: Avalon Executive Center 4400 Route 9 South Suite 3100 Freehold, New Jersey, USA 10
Slide 11: Operating Laboratories
Operating Laboratories Weill Cornell Medicine, USA Co-development program with cGMP Cell Engineering Facility (Dr. Yen-Michael Hsu) Standardization of human stem cell derived exosomes bio-production #209 1 Sve? SE AVALON Beijing Lu Daopei Hospital, China Exosome isolation kits manufacturing Exosome
Slide 12: Paradigm Shifts in Medicine
Paradigm Shifts in Medicine Biochemical i Pharmaceuticals Tests Tissue Biopsy Genomics Liquid Biopsy Cellular Therapeutics Proteomics Metabolomics ctDNA, cfDNA, CTC, Regenerative Medicine: Stem / Progenitor Cells Cellular immunotherapy: CAR-T, CAR-NK, DC, CIK,....etc. Exosomes Shaping the basis of o
Slide 13: Overview of Exosomes (Extracellular Vesicles)
Overview of Exosomes (Extracellular Vesicles) Exosomes — Nano-sized Molecular Shuttles TEM + Nano-vesicles, 50-150nm + Have a common set of membrane and cytosolic proteins + Contain cell-type specific protein, mRNA, and miRs + Role in transfer of RNA and protein for cell-cell ~ interactions and sign
Slide 14: Overview of Exosomes (Extracellular Vesicles)
Overview of Exosomes (Extracellular Vesicles) ae “Sa * Exosomal biomarkers as disease- s Peto AY 7) i Preface) diagnostics: “Liquid Biopsy” : * Stem cell-derived exosomes as Enzymes = ER regenerative therapeutics Sey - noe seme Cytoskeletal Proteins * Engineered exosomes as novel carrier for targete
Slide 15: Liquid Biopsy
Liquid Biopsy Exosomes for personalized medicine What does a liquid biopsy look for? Liquid 10) pee . Tumor sheds cancer cells into blood (circulating tumor cells) . Tumor sheds bits of cancer’s genetic material into blood (circulating tumor DNA) % oe < . Parts of cancer cells get ey “Og ot s pinche
Slide 16: Cellular Therapeutics / CAR-T: Investment by Big Pharmas
Cellular Therapeutics / CAR-T: Investment by Big Pharmas Novartis receives first ever FDA approval for a CAR-T cell therapy, THE WALL STREET JOURNAL. 20,20: Kymriah(TM) (CTLO19), for oe ‘ oer fren Se tory an han . Celgene to Buy Juno Therapeutics for $9 Billion relapsed at least twice Ebhe New York
Slide 17: # of Studies
# of Studies # of Studies QAM PMO DO ONT ADO KHHOHVGOGOD: NOAA SSPE PPE PPE OE Years source: www.clinicaltrials.gov * Data up to August 2017 v7
Slide 18: Avalon Ecosystem: Subsidiaries & Joint Ventures
Avalon Ecosystem: Subsidiaries & Joint Vent Avalon believes the future of medicine will evolve toward cell-based therapeutics and diagnostics. AVALON EXOSOME TECHNOLOGY Technologies \SENEXOSOME ’) AVACTIS AVALON HEALTHCARE FACILITY spv: Avalon RT9 Properties, ttc AVALON GMP FACILITY Jv: Nanjing Epic
Slide 19: Subsidiaries/JV Structure Adds Flexibility & Focus
Subsidiaries/JV Structure Adds Flexibility & Focus Avalon’s Success Subsidiaries/JV are functional or therapeutic area focused focused research and development ‘ocused deal-making ‘undraising and investor flexibility 1 Sve. ee AVALON 19
Slide 20: Avalon Subsidiaries: Genexosome Technologies (GT)
Avalon Subsidiaries: Genexosome Technologies (GT) b Technologies (GENEXOSOME 1 de. Fe AVALON
Slide 21: Avalon-GT Exosome Isolation System
Avalon-GT Exosome Isolation System Avalon-GT Exosome Isolation System A Single Proprietary Core Technology Platform which is: Versatile, Highly Scalable, Enhanced Purity Advantages Over Traditional Ultra-Centrifugation (UC) Methodology + Fast turn-around time (within minutes) vs. traditional UC (1-2
Slide 22: Avalon-GT's Operational / Commercial Program
Avalon-GT’s Operational / Commercial Program ef Sve. iS AVALON 22
Slide 23: Avalon-GT's Operational Program
Avalon-GT’s Operational Program 7 In commercialization stage 2019 Q!1: ¢ Scale up manufacturing and increase distributorship GET™ “ONE Drop” Exosome Isolation Kit (for Serum/Piasma) GET™Exosome Isolation Kit for Serum/Plasma GET™ Exosome Isolation Kit (for Cell Culture Medium) ee ee GET™ Exosome Iso
Slide 24: Avalon-GT's Operational Program /2
Avalon-GT’s Operational Program /2 2 “Liquid Biopsy” to Criteria Identify Disease-Specific Exosomal Biomarkers * Unmet medical need with global market value >$1B -Industry aes ss 7 n 7 A nt Programs) * Prestigious clinical partners with authoritative Pis * Abundant bio-specimens & patient population
Slide 25: Avalon-GT's Operational Program /2
Avalon-GT’s Operational Program /2 ef Sve. 3S AVALON Current Clinical Programs Oral Cancer NASH* Leukemia MRD** Colorectal Cancer Macular Degeneration Novel Exosomal Biomarker v v Clinical Partners Weill Cornell A China Beijing Stomatology Hospital PCT Weill Cornell, NYPH, UCSD Pandlg, Beijing Frien
Slide 26: Avalon-GT Diagnostic Product Development Pipeline
Avalon-GT’s Operational Program )2 Avalon-GT Diagnostic Product Development Pipeline Exosome-Based Liquid Biopsy Indication Oral Cancer NASH Leukemia MRD Colorectal CA Macular Degen. ef Sve. iS AVALON Research Exosomal Biomarker identified: miR-185 Exosomal Biomarker identified Exosomal Biomarker id
Slide 27: Relative level of saliva-based exosomal miR-185
(pre-cancerous state) (malignant) Relative level of saliva-based exosomal miR-185 (cancer suppressor) 21
Slide 28: Avalon-GT's Liquid Biopsy Program - Oral Cancer
Avalon-GT’s Liquid Biopsy Program - Oral Cancer Liquid Biopsy (Exosome Diagnostics) aes Oral Deakonlakia > Gal Cancer (pre-cancerous state) (malignant) Relative level of saliva-based exosomal miR-185 (cancer suppressor) Sve. Be AVALON Exosome Meh bio-engineered MSC stem cells over-expressing > miR-1
Slide 29: Avalon-GT's Program - Oral Cancer
Avalon-GT’s Program - Oral Cancer Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker “miR-185” as Dual Diagnostic and Therapeutic Target for Oral Cancer 28-01-2019 Study Accepted as Poster Presentation at th
Slide 30: Avalon-GT's Exosome Therapeutic Pipeline
Avalon-GT’s Exosome Therapeutic Pipeline Program AVA-201 (MSC-Exo-miR185) AVA-202 (Angiogenic Exosome) AVA-203 (MSC-Exosome) 1 Sve? SE AVALON Pre-clinical Design control / IND enabling Initiation by 201902 Initiation by 201902 Clinical Development Regulatory Path Safety Efficacy _— Pivotal ee Initia
Slide 31: Avalon-GT's Operational Program: Stem Cell Derived Exosomes
Avalon-GT’s Operational Program 73 3 Completion of standardization SOP by end of 2019 Q1; Clinical-Grade Initiation of strategic product co-development; Acceleration of commercialization Stem Cell Derived Exosome Bio-production for Regenerative Applications Stem Cell Exosome Products Standardization
Slide 32: Avalon Subsidiary: Avactis Biosciences
Avalon Subsidiary: Avactis Biosciences sve. ae AvA gy AVACTIS BIlOosctleENCE § AVACTIS acronym: AVAlon Cellular Therapy Integrated System A wholly owned subsidiary of Avalon GloboCare Corp. Avactis Biosciences is dedicated to integrate and optimize global scientific and clinical resources in cellula
Slide 33: Avalon/Avactis — Arbele Joint Venture
Avalon/Avactis — Arbele Joint Venture AP AP NEWS Top Stoves Tops Video Lis Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co- develop Next Generation Multi-Targeted CAR-T Cellular Immunotherapy ‘Avalon GloboCare Corp. J Arbele Limited, ere Kong Science & Technology Park me ¥ Arbel
Slide 34: Avalon/Avactis Business Focus: Cellular Therapeutics
Avalon/Avactis Business Focus: Cellular Therapeutics Novartis receives first ever FDA approval for a CAR-T cell therapy, Problems with first Kymriah(TM) (CTLO19), for generation CAR-T children and young adults with B- technolo gy: cell ALL thatis refractory or has relapsed at least twice * Single ta
Slide 35: Avalon/Avactis — Arbele Joint Venture
Avalon/Avactis — Arbele Joint Venture Avalon GloboCare Announces Filing of Provisional Patent Applications for AVA- 101, a Novel Transposon-Based, Multi- Targeted CAR-T Therapy AVA-101 designed to enhance efficacy and overcome safety challenges of current CAR-T immune-oncology therapeutics AVA-101 r
Slide 36: Avalon/Avactis Cellular Therapy Platform
Avalon/Avactis Cellular Therapy Platform Avalon Integrates Key Verticals for Successful Cellular Therapy Program . Proprietary CAR constructs Novel, proprietary therapeutic targets Non-viral vector; transposon technology “Safety-switch” mechanism Multiple therapeutic targets (incorporation in progre
Slide 37: Avalon/Avactis Cellular Therapy Platform
Avalon/Avactis Cellular Therapy Platform Joint Venture Between Avalon/Avactis and Arbele Limited For Hematologic Malignancies * Design and bio-production of non-viral vector (transposon-based) transduced CAR-T immunotherapy for B-ALL, Lymphoma, and Multiple Myeloma + Targets: CD19, CD22, CD123, Dual
Slide 38: Avalon Therapeutic Pipeline
Avalon Therapeutic Pipeline Pi linical Design control / Clinical Development “eran precces INDenabling Safety — Efficacy _—Pivotal AVA-101 Initiation by Initiation by (CD19xCD22 CAR-T) 201902 202001 US FDA & China FDA Regulatory Pathway 38
Slide 39: Avalon Therapeutic Pipeline
Avalon Therapeutic Pipeline - Design control / Clinical Development Program Pre-clinical 6 IND enabling Safety Efficacy Pivotal Regulatory Pathway AVA-101 Initiation by Initiation by (CD19xCD22 CAR-T) Sea 2019. Q2 202001 US FDA & China FDA eeieds : pep US FDA China FDA (MSC-Exo-miR185) 201902 AVA 20
Slide 40: Avalon's Near-Term Milestones & Investment Highlights: GT
Avalon’s Near-Term Milestones & Investment Highlights: GT Exosome isolation system / research tools (commercialization stage): * 2019-Q1: Add commercial, academic, and R&D customers * 2019-Q1: Add distribution partners (USA, China) * 2019-1: Scale up manufacturing (USA, China) Bio-production of clin
Slide 41: Avalon's Near-Term Milestones & Investment Highlights: Avactis
Avalon’s Near-Term Milestones & Investment Highlights: Avactis 2019-Q1: Complete USPTO provisional patent filing of AVA-101 (a novel, transposon-based, bispecific (CD19 X CD22) CAR-T with “safety switch” control system); JV with Arbele Limited * 2019-Q2: Disease model testing for AVA-101; complete v
Slide 42: Equity Snapshot
Equity Snapshot Avalon GloboCare Corp. Exchange NASDAQ: AVCO Recent Stock Price* $3.57 Shares Outstanding** 74,310,751 Market Capitalization $265.3M Average Volume* 715K Float 21.3M shares Insider Ownership 71.3% Fiscal Year-End December 31, 2018 * As of March 5, 2019 ** As of January 15, 2019 in la
Slide 43: Avalon GloboCare Corp. Contact
le, 3X AVALON GLOBOCARE CORP. Nasdaq: AVCO Contact: David Jin, MD, PhD President & CEO Email: david@avalon-globocare.com
Avalon GloboCare — Investor Presentation (March 2019) on 6ix